Saminvest

Saminvest is a Stockholm-based corporate venture vehicle backed by the Swedish state, set up to strengthen domestic venture capital by anchoring new fund managers rather than investing directly in operating companies. The mandate centers on healthcare adjacent to broader innovation, with disclosed sub-vertical interest spanning digital health and biotech. Limited public information is available about specific portfolio companies or named investment partners, and the fund does not publicly identify itself with an artificial intelligence thesis. Activity sits inside a fund-of-funds structure aimed at building durable Swedish life sciences capacity over multi-year cycles.

Saminvest concentrates on Seed and Series A entry points through the underlying managers it capitalizes, with check sizes for direct co-investments described in the range of one to five million dollars. Geographic focus is firmly Sweden, with attention to managers operating across the wider Nordic region. Because deployment generally flows through partner funds, founders typically encounter Saminvest indirectly via a portfolio manager rather than as a lead on a primary round. The pacing reflects an institutional, capital-formation rhythm rather than a high-volume direct investment program.

For founders, the practical implication is that engagement begins by identifying which downstream Swedish life sciences fund Saminvest has supported and then approaching that manager on its own terms. Direct cold outreach to Saminvest is rarely the right path for an early-stage company seeking primary financing. Founders building digital health or biotech businesses with Swedish ties may benefit indirectly from the deeper capital pool Saminvest is helping create, particularly when raising alongside emerging local managers. Expectations should be calibrated to a public-mission investor focused on ecosystem outcomes rather than rapid deal turnaround.